Globally, nearly 300 million people are suffering with alcohol use disorders, leading to nearly 300 deaths yearly. 

To date, drugs for managing alcohol abuse have not been part of EML. 

This year WHO made a significant move in recognizing the public health burden of alcohol abuse by including its treatment in the EML. 

Both Acamprosate and Naltrexone are WHO (2016) recommended medication to treat alcohol dependance. 

This inclusion will aid in the implementation of the Global Alcohol Action Plan 2022-2030, which outline initiatives to improve the prevention and treatment capacity of health and social care systems for alcohol use disorders as envisioned by the 75th World Health Assembly in 2022.